Quick Answer
MYRIAD GENETICS INC reported R&D Expense of $106.80 million for fiscal year 2025.
MYRIAD GENETICS INC R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $106.80M | -5.8% |
| 2024 | $113.40M | +27.8% |
| 2023 | $88.70M | +3.9% |
| 2022 | $85.40M | +4.3% |
| 2021 | $81.90M | +11.7% |
| 2020 | $73.30M | -5.1% |
| 2020 | $77.20M | -10.1% |
| 2019 | $85.90M | +21.3% |
| 2018 | $70.80M | -4.8% |
| 2017 | $74.40M | +5.4% |
| 2016 | $70.60M | -6.5% |
| 2015 | $75.50M | +11.9% |
| 2014 | $67.50M | +25.7% |
| 2013 | $53.70M | +25.9% |
| 2012 | $42.65M | +53.7% |
| 2011 | $27.75M | +26.9% |
| 2010 | $21.87M | +22.1% |
| 2009 | $17.91M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $28.20M | -1.1% | +10.2% |
| June 30, 2025 | $25.60M | -5.5% | -6.9% |
| March 31, 2025 | $27.50M | +10.4% | -3.5% |
| September 30, 2024 | $28.50M | +18.8% | +5.2% |
| June 30, 2024 | $27.10M | +27.8% | +8.8% |
| March 31, 2024 | $24.90M | +10.7% | +3.8% |
| September 30, 2023 | $24.00M | +17.1% | +13.2% |
| June 30, 2023 | $21.20M | +4.4% | -5.8% |
- MYRIAD GENETICS INC showed a decrease of -5.8% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2025 period, MYRIAD GENETICS INC’s r&d expense has grown by 496.2% (from $17.91 million to $106.80 million).
- The most recent figure is from MYRIAD GENETICS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: